Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve second-line...

Full description

Bibliographic Details
Main Authors: Roland Hubaux, Fabian Vandermeers, Jean-Philippe Cosse, Cecilia Crisanti, Veena Kapoor, Steven M. Albelda, Céline Mascaux, Philippe Delvenne, Pascale Hubert, Luc Willems
Format: Article
Language:English
Published: European Respiratory Society 2015-10-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/1/2/00028-2015.full

Internet

http://openres.ersjournals.com/content/1/2/00028-2015.full

Similar Items